Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.

We review the different definitions of intolerance used in sponsored trials and in clinical practice, and we discuss how such definitions impact on the management of AEs. We summarize how to evaluate QoL during treatment with TKIs and how to include ponatinib among possible option for intolerant patients.